



PRESS RELEASE

COMPLETION OF THE ACQUISITION OF DENTAL LOCAL ANESTHETIC PORTFOLIO ASSETS FROM 3M COMPANY

Capua (Italy), August 1st, 2023 – Following the press release published on May 2nd, 2023 and available on the company's website at www.pierrelgroup.com (section "*News&Press/Comunicati stampa*"), Pierrel S.p.A. ("**Pierrel**") announces that today it has given complete execution to the agreements signed on May 2nd, 2023 and related to the transaction ("**Transaction**") consisting in the purchase by Pierrel of certain contracts, permits, including marketing authorizations, and intellectual property related to Ubistesin™, Xylestesin™ and Mepivastesin™ products (articaine, lidocaine and mepivacaine-containing products for local anaesthesia) used in dental care as well as related syringe and needle products, from 3M Company, for a total purchase price of 70 million dollars, subject to other adjustments.

The main terms and conditions of the Transaction have been fully described in the prospectus relating to the rights issue offering to holders of ordinary shares and admission to trading on the Euronext Milan market, organized and managed by Borsa Italiana S.p.A, of Pierrel's new ordinary shares resulting from a rights issue offering pursuant to Article 2441, par. 1, of the Italian Civil Code, approved by Consob on July 7th, 2023, published on the company's website at www.pierrelgroup.com (section "*Investor relations/Governance documents/Documentazione per gli azionisti/Aumenti di capitale*").

* * *

Pierrel S.p.A. is a pharmaceutical industry provider specializing in the development, production, registration and licensing of synthetic drugs - regional local anesthetics - and medical devices for the oral health sector. Based in Capua (CE), listed on the EXM market organized and managed by Borsa Italiana, Pierrel is authorized by EMA ("European Medicines Agency") and FDA ("Food and Drug Administration") for the aseptic production of injectable drugs. After over seventy years of experience, Pierrel is one of the world's leading manufacturers of own-brand dental anesthetics, including Orabloc® marketed in most of the world markets, such as Canada, USA, Russia and Europe and with a significant market share in the USA. Real time information on the company and all press releases are available on the new website www.pierrelgroup.com

For further information:

Pierrel S.p.A.
Investor Relator
Dott. Fulvio Citaredo
E-mail: investor.relations@pierrelgroup.com
tel. +39 0823 626 111
fax +39 0823 626 228

Spriano Communication & Partners S.r.l.
Media Relations
Cristina Tronconi
E-mail: ctronconi@sprianocommunication.com
tel. + 39 3460477901
Fiorella Girardo
E-mail: fgirardo@sprianocommunication.com
tel. +39 3488577766